➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Boehringer Ingelheim
Merck
Harvard Business School

Last Updated: January 18, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Alisertib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Alisertib?

Alisertib is an investigational drug.

There have been 49 clinical trials for Alisertib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2012.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are eighteen US patents protecting this investigational drug and two hundred and twenty-three international patents.

Recent Clinical Trials for Alisertib
TitleSponsorPhase
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerNational Cancer Institute (NCI)Phase 1/Phase 2
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerM.D. Anderson Cancer CenterPhase 1/Phase 2
Osimertinib With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1

See all Alisertib clinical trials

Clinical Trial Summary for Alisertib

Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib

See all Alisertib clinical trials

US Patents for Alisertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Alisertib   Start Trial Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Alisertib   Start Trial Combinations of LSD1 inhibitors for use in the treatment of solid tumors Oryzon Genomics, S.A. (Madrid, ES)   Start Trial
Alisertib   Start Trial Combination of aurora kinase inhibitors and anti-CD30 antibodies Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Alisertib   Start Trial Combination of aurora kinase inhibitors and anti-CD20 antibodies Millennium Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Alisertib   Start Trial Tetrazolones as a carboxylic acid bioisosteres Rigel Pharmaceuticals, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Alisertib

Drugname Country Document Number Estimated Expiration Related US Patent
Alisertib Brazil BR112012020557 2030-02-19   Start Trial
Alisertib Canada CA2788774 2030-02-19   Start Trial
Alisertib China CN102770024 2030-02-19   Start Trial
Alisertib China CN104031049 2030-02-19   Start Trial
Alisertib European Patent Office EP2536279 2030-02-19   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Boehringer Ingelheim
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.